Congestive Heart Failure Antiarrhythmic Drugs Induced by Six of the Newer

The incidence of drug-induced congestive heart failure with several newer antiarrhythmic agents including encainide, ethmozine, lorcainide, mexiletine, propafenone and tocainide was determined in a group of 407 patients who underwent 1,133 drug tests. The incidence rate ranged from 0.7% with lorcainide to 4.7% with propafenone. Congestive heart failure was present in 167 patients (41%) who underwent 491 drug trials. Congestive failure was induced in 15 (9%) of these 167 patients and involved 19 (3.9%) of

[1]  M. Rubenfire,et al.  Hemodynamic Effects of Antiarrhythmic Drugs , 1991, Journal of clinical pharmacology.

[2]  L. Soyka.  Safety of encainide for the treatment of ventricular arrhythmias. , 1986, The American journal of cardiology.

[3]  G. Francis.  Development of arrhythmias in the patient with congestive heart failure: pathophysiology, prevalence and prognosis. , 1986, The American journal of cardiology.

[4]  D. Roden,et al.  Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. , 1986, The American journal of cardiology.

[5]  M. Brodsky,et al.  Propafenone therapy for ventricular tachycardia in the setting of congestive heart failure. , 1985, American heart journal.

[6]  J. Rutledge,et al.  Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias. , 1985, Journal of the American College of Cardiology.

[7]  M. Gheorghiade,et al.  Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. , 1985, American heart journal.

[8]  B. Lown,et al.  Effects of oral mexiletine on left and right ventricular function. , 1984, The American journal of cardiology.

[9]  B. Lown,et al.  Use of nonsustained ventricular tachycardia as a guide to antiarrhythmic drug therapy in patients with malignant ventricular arrhythmia. , 1983, American heart journal.

[10]  T. Graboys,et al.  Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. , 1982, The American journal of cardiology.

[11]  J. Williams,et al.  Safety evaluation of tocainide in the American Emergency Use Program. , 1980, American heart journal.

[12]  B. Lown,et al.  Congestive heart failure caused by oral disopyramide. , 1980, The New England journal of medicine.

[13]  T. Graboys,et al.  Sudden cardiac death--management of the patient at risk. , 1980, Current problems in cardiology.

[14]  L. Cobb,et al.  Recurrent ventricular fibrillation and modes of death in survivors of out-of-hospital ventricular fibrillation. , 1975, The New England journal of medicine.